<DOC>
	<DOCNO>NCT01365507</DOCNO>
	<brief_summary>This trial conduct Asia North America . The aim trial compare efficacy safety insulin degludec/insulin aspart ( IDegAsp ) daily insulin-naïve subject type 2 diabetes mellitus use two different titration algorithm ( dose individually adjust ) add-on subject 's ongoing treatment metformin .</brief_summary>
	<brief_title>Efficacy Safety Insulin Degludec/Insulin Aspart Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Type 2 diabetes ( diagnose clinically ) 24 week longer prior randomisation ( visit 2 ) Insulin naïve subject ( Allowed : Previous short term insulin treatment longer equal 14 day total ; Treatment hospitalisation gestational diabetes allow period longer 14 day total ) Current treatment : Metformin alone metformin combination 1 2 additional OADs ( oral antidiabetic drug ) include insulin secretagogue ( sulfonylurea glinide ) , dipeptidyl peptidase IV ( DPPIV ) inhibitor , alphaglucosidase inhibitor thiazolidinediones ( TZDs ) unchanged dose least 12 week prior randomisation ( visit 2 ) . Metformin dose , alone combination ( include fix combination ) , must least 1000 mg daily HbA1c ( glycosylated haemoglobin ) 7.010.0 % ( inclusive ) BMI ( Body Mass Index ) equal 45 kg/m^2 Ability willingness adhere protocol include self measurement plasma glucose Treatment GLP1 ( glucagon like peptide ) receptor agonist within last 12 week prior randomisation ( visit 2 ) Recurrent severe hypoglycaemia ( one severe hypoglycaemic event last 12 month ) hypoglycaemic unawareness judge Investigator ( trial physician ) Previous participation trial . Participation define randomise . Rescreening allowed recruitment period Known suspect hypersensitivity trial product relate product The receipt investigational drug within 4 week prior randomisation ( visit 2 ) Anticipated significant lifestyle change study , e.g . shift work ( include permanent night/evening shift worker ) well highly variable eat habit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>